Low dose intradermal vaccination against hepatitis B in mentally retarded patients. 1988

R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
Department of Virology, Erasmus University Rotterdam, The Netherlands.

Ninety-two patients and 28 staff members of an institute for mentally retarded patients were immunized intradermally with 2 microgram doses hepatitis B vaccine (HB-Vax), initially at month 0 and 1, and after evaluation followed by two booster injections at month 5 and 10, respectively. Blood samples were taken at months 2 and 11. Seroconversion rates of the two groups were similar on both occasions. Titre distributions for mentally retarded patients and staff members corrected for age, side effects and sex using multiple regression were significantly different at month 2 (p = 0.05) but not at month 11. Geometric mean titres for mentally retarded patients and staff members were 39 and 67 at month 2, respectively, and 1082 and 672 IU l-1 at month 11, respectively. Percentage anti-HBs/a(w) differed significantly between patients and staff members. Side effects, largely local (pigmentation), were observed with a frequency of about 35% in both mentally retarded patients and staff members. Since 92% of the mentally retarded patients had anti-HBs titres greater than 10 IU l-1 and approximately equal to 80% greater than 100 IU l-1, low dose vaccination, four injections by intradermal route, seems to be a suitable cost-reducing immunization system in institutes for mentally retarded patients.

UI MeSH Term Description Entries
D008297 Male Males
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D005260 Female Females
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012882 Skin Tests Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity. Skin Test,Test, Skin,Tests, Skin
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014761 Viral Hepatitis Vaccines Any vaccine raised against any virus or viral derivative that causes hepatitis. Hepatitis, Viral, Vaccines,Hepatitis Vaccines, Viral,Vaccines, Viral Hepatitis
D017325 Hepatitis B Vaccines Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced. Hepatitis B Vaccine,Vaccine, Hepatitis B,Vaccines, Hepatitis B

Related Publications

R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
September 1989, The Journal of infection,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
March 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
January 1991, The Journal of the American Board of Family Practice,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
November 1991, European journal of epidemiology,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
September 1986, The New Zealand medical journal,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
January 1993, Scandinavian journal of infectious diseases,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
December 1986, Lancet (London, England),
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
September 1988, Orvosi hetilap,
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
January 1984, Hepatology (Baltimore, Md.),
R A Heijtink, and A A Breukers, and G den Hartigh, and R W Schepman, and P I Schmitz, and S W Schalm, and N Masurel
January 2005, ASAIO journal (American Society for Artificial Internal Organs : 1992),
Copied contents to your clipboard!